Discovery of a novel series of quinolone and naphthyridine derivatives as potential topoisomerase I inhibitors by scaffold modification

J Med Chem. 2009 Sep 24;52(18):5649-61. doi: 10.1021/jm900469e.

Abstract

A novel series of topoisomerase I (Top I) inhibitors were designed on the basis of camptothecin using scaffold modification strategy. Thirty-one new compounds were synthesized and evaluated for anticell proliferation activity. The most potent compound 26 presented a significant inhibitory effect on Top I, leading to Top I-mediated cleavage and influences on Top I expression at the cellular level. Moreover, 26 was proved to induce cell death via apoptosis and accelerated DNA strand breaks without significant alteration in cell cycle populations. All of the experimental results herein indicated that 26 could interact with DNA-Top I complex and induce cancer cell apoptosis to produce antitumor effects. The in vivo evaluation of 26 on the growth of HT-29 tumor xenografts in nude mice suggested its therapeutic potential for further development.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Antineoplastic Agents / chemistry
  • Antineoplastic Agents / pharmacology
  • Antineoplastic Agents / therapeutic use
  • Cell Line, Tumor
  • Cell Proliferation / drug effects
  • DNA / metabolism
  • Drug Discovery*
  • Enzyme Inhibitors / chemistry
  • Enzyme Inhibitors / pharmacology
  • Enzyme Inhibitors / therapeutic use
  • Female
  • Humans
  • Mice
  • Mice, Nude
  • Models, Molecular
  • Molecular Conformation
  • Naphthyridines / chemistry*
  • Naphthyridines / pharmacology*
  • Naphthyridines / therapeutic use
  • Neoplasms / drug therapy
  • Neoplasms / pathology
  • Quinolones / chemistry*
  • Quinolones / pharmacology*
  • Quinolones / therapeutic use
  • Topoisomerase I Inhibitors*
  • Transplantation, Heterologous

Substances

  • Antineoplastic Agents
  • Enzyme Inhibitors
  • Naphthyridines
  • Quinolones
  • Topoisomerase I Inhibitors
  • DNA